Targets › BRADYKININ
1 program from 1 company in 2 trials: 2 Phase 1; Immunology.
Open in Phaseline: the race on BRADYKININ, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute for Asthma and Allergy | Deucrictibant XR tablet Bradykinin B2 receptor antagonist | BRADYKININ | Phase 1 | Hereditary Angioedema (HAE) | – |
Hereditary Angioedema (HAE) (2)
small molecule (1)
Institute for Asthma and Allergy (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.